Blood Cancer Breast Cancer Lung Cancer Pancreatic Cancer

Woodland Boy Fighting Leukemia Meets Santa At Golden 1 Center North Pole CBS Sacramento [Video]

SACRAMENTO (CBS) – A 7-year-old Woodland boy diagnosed with leukemia wished to meet Santa Claus and have a hamburger dinner at the North Pole—and that wish was granted.

In July 2021, Santa sent a video message to Pastor to let him know they would meet on November 1 in Sacramento. The rest was a surprise.

READ MORE: Remains Of Fairfield Homicide Victim Found In Monterey County; Travis AFB Airman Among 3 Arrested

“It melts my heart, especially in this time that…my sister’s not here. This means a lot to me for him to be happy,” said Teresa Silva, Pastor’s aunt. 

He arrived at the Downtown Sacramento Macy’s in a limo Monday morning and was greeted by store employees dressed in their “North Pole best.” Inside waiting, Santa Claus and a workshop space transformed to take Pastor to the North Pole like he wished to do.

He wrote his letter to Santa Claus, with specifics on their day: hamburgers for the …

Watch/Read More
Blood Cancer

MagnetisMM-3: elranatamab in relapsed/refractory multiple myeloma [Video]

Alexander M. Lesokhin, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses safety results from the MagnetisMM-3 trial (NCT04649359), a Phase II, open-labeled, multicenter, non-randomized trial evaluating elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody in patients with relapsed/refractory multiple myeloma. Patients enrolled were refractory to at least 1 proteasome inhibitor, 1 immunomodulatory drug, and 1 anti-CD38 antibody. Preliminary results of MagnetisMM-3 in patients with relapsed/refractory myeloma and no prior BCMA-targeted treatment suggest that 76 mg of elranatamb adminstered once weekly with a 2-step-up priming regimen is well tolerated, with no grade 3 cytokine release syndrome or immune effector cell-assciated neurotoxicity syndrome (ICANS) observed. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Blood Cancer

CAR-T in multiple myeloma: cilta-cel & ide-cel [Video]

Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, shares his thoughts on how the addition of ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel) to the treatment paradigm is adding value to the treatment of patients with multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.